Tritanrix-HBV

Tritanrix-HBV is a quadrivalent combination vaccine developed by GSK Biologicals to provide active immunity against diphtheria, tetanus, pertussis (whooping cough), and hepatitis B in infants and children. The formulation consists of purified diphtheria and tetanus toxoids, a suspension of inactivated whole-cell *Bordetella pertussis* (DTPw), and recombinant hepatitis B surface antigen (HBsAg) produced in yeast cells. These antigens are adsorbed onto aluminum hydroxide and aluminum phosphate to enhance the immune response. By combining these four components into a single injection, the vaccine was designed to simplify pediatric immunization schedules and improve compliance. Although it was widely used globally and received marketing authorization in the European Union in 1996, the authorization was withdrawn in 2011 as clinical practice in many regions shifted toward acellular pertussis (DTPa) combinations and more complex pentavalent or hexavalent vaccines.

Brand names

Tritanrix-HBVTritanrix HepB

Other names

DTPw-HBV vaccinediphtheria, tetanus, pertussis (whole cell) and hepatitis B (rDNA) vaccine (adsorbed)DTP-HBV